Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Palbociclib|DRUG: Capecitabine|DRUG: Exemestane|DRUG: Fulvestrant
Sponsor: Spanish Breast Cancer Research Group
Collaborators: Pfizer|AstraZeneca